Earnings Call · Q1 FY2025·2025-05-08

Q1 25EPS +5.41%·Rev n/aQ4 24EPS -32.26%·Rev n/aQ3 24EPS +30.77%·Rev n/aQ2 24EPS +12.12%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Stephanie Fagan — Investor Relations or Corporate Communications

Rob Barrow — Chief Executive Officer

Matt Wiley — Chief Commercial Officer

Dan Karlin — Chief Medical Officer or Clinical Development Lead

−2.0%1d on move date−2.7% vs SPY3d−2.1%5d−0.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access